Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL
2004 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL
Pfreundschuh, M.; Truemper, L. H.; Kloess, M.; Schmits, R.; Feller, A. C.; Rudolph, C. & Reiser, M. et al. (2004)
Blood, 104(3) pp. 626-633. DOI: https://doi.org/10.1182/blood-2003-06-2094
Documents & Media
Details
- Authors
- Pfreundschuh, Michael; Truemper, Lorenz H.; Kloess, Marita; Schmits, Rudolf; Feller, A. C.; Rudolph, C.; Reiser, M.; Hossfeld, D. K.; Metzner, Bernd; Hasenclever, Dirk; Schmitz, Norbert; Glass, Bertram; Rube, C.; Loeffler, Markus
- Abstract
- The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21) is standard chemotherapy for aggressive lymphomas. To determine whether CHOP given every 2 weeks (CHOP-14) or the addition of etoposide (CHOEP-21, CHOEP-14) can improve results in patients ages 18 to 60 years with good prognosis (normal lactic dehydrogenase [LDH] level), 710 patients were randomized to 6 cycles of CHOP-21, CHOP-14, CHOEP-21 (CHOP plus etoposide 100 mg/m(2) days 1-3), or CHOEP-14 in a 2 x 2 factorial study design. Patients in the biweekly regimens received granulocyte colony-stimulating factor (G-CSF) starting from day 4. Patients received radiotherapy (36 Gy) to sites of initial bulky disease and extra-nodal disease. CHOEP achieved better complete remission (87.6% versus 79.4%; P = .003) and 5-year event-free survival rates (69.2% versus 57.6%; P = .004, primary end point) than CHOP, whereas interval reduction improved overall survival (P = .05; P = .044 in the multivariate analysis). Although the CHOEP regimens induced more myelosuppression, all regimens were well tolerated. CHOEP should be the preferred chemotherapy regimen for young patients with good-prognosis (normal LDH level) aggressive lymphoma.
- Issue Date
- 2004
- Status
- published
- Publisher
- Amer Soc Hematology
- Journal
- Blood
- ISSN
- 0006-4971